Volume 1, No. 2 – February, 2004
RED MEAT CAN RAISE DIABETES RISK
High intake of the type of iron found in red meat may increase risk of developing Type II Diabetes, an American study has found.
Dr. Rui Jang and colleagues from the Harvard School of Public Health evaluated data gathered over a 12-year period regarding over 38,000 men. The data showed the risk of developing Type II Diabetes or “Adult Onset” diabetes increased with the amount of red meat in the diet. Other sources of iron did not contribute to the increased risk of developing diabetes.
More information is available in the American Journal of Clinical Nutrition, January 2004.
NEW ORAL TYPE II DIABETES DRUG MAY ASSIST WEIGHT STABILIZATION
A new Type II Diabetes treament called Sucanon may contribute to weight stabilization or even weight loss, says a company that is starting the marketing of a new diabetes drug called Sucanon.
Sucanon has been approved in Mexico for reduction of blood sugar levels and relief of other symptoms of Type II Diabetes and will go on sale there shortly. Sucanon may also become available for use in the U.S. market by internet purchase from pharmacies in Mexico.
More information is available at the website www.biotechltd.com
MORE MAGNESIUM IN DIET LOWERS RISK OF DEVELOPING TYPE II DIABETES
Consuming more foods high in magnesium — found particularly in nuts, whole grains and leafy green vegetables — may lower risk of developing Type II diabetes, according to studies carried out at Harvard Medical School.
One of the studies evaluated nutrition in over 80,000 female nurses, followed for 18 years, and more than 40,000 male health professionals, followed for 12 years. With both women and men, the more magnesium consumed, the lower the risk of developing Type II Diabetes.
More information is available in Diabetes Care, January 2004.
NEW INJECTED DIABETES DRUG REDUCES TYPE II DIABETES SYMPTOMS
A new injected drug called Exenatide, currently being evaluated by the FDA, has shown significant reductions in blood glucose levels of patients who do not achieve satisfactory blood glucose control with existing drugs.
The target market for the drug, when approved, will be Type II or “adult-onset” diabetics who are not injecting insulin. The company plans marketing exenatide in an injectable pen / cartridge delivery system.
More information is available at the website http://www.amylin.com